Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries.
Antibiotic utilization
Antimicrobial resistance
Pseudomonas aeruginosa
Serbia
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
17
11
2022
accepted:
10
05
2023
medline:
26
7
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR). The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006-2020), and the reported AMR in Pseudomonas aeruginosa (2013-2020) in Serbia and to compare with data from eight European countries (2015-2020). Joinpoint regression was used to analyse antibiotic utilization data (2006-2020) and the reported AMR in Pseudomonas aeruginosa (2013-2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries. There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aeruginosa, Serbia (p < 0.05) (2018-2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseudomonas aeruginosa an increased trend was observed, Serbia (2013-2020). A decrease in both the utilization of aminoglycosides, Serbia (p < 0.05) (2006-2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015-2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015-2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015-2020). The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.
Sections du résumé
BACKGROUND
BACKGROUND
In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR).
AIM
OBJECTIVE
The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006-2020), and the reported AMR in Pseudomonas aeruginosa (2013-2020) in Serbia and to compare with data from eight European countries (2015-2020).
METHOD
METHODS
Joinpoint regression was used to analyse antibiotic utilization data (2006-2020) and the reported AMR in Pseudomonas aeruginosa (2013-2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries.
RESULTS
RESULTS
There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aeruginosa, Serbia (p < 0.05) (2018-2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseudomonas aeruginosa an increased trend was observed, Serbia (2013-2020). A decrease in both the utilization of aminoglycosides, Serbia (p < 0.05) (2006-2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015-2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015-2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015-2020).
CONCLUSION
CONCLUSIONS
The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.
Identifiants
pubmed: 37284904
doi: 10.1007/s11096-023-01603-y
pii: 10.1007/s11096-023-01603-y
pmc: PMC10246517
doi:
Substances chimiques
Ceftazidime
9M416Z9QNR
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Aminoglycosides
0
Fluoroquinolones
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-998Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 451-03-68/2022-14/200161
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Jinks T, Lee N, Sharland M, et al. A time for action: antimicrobial resistance needs global response. Bull World Health Organ. 2016;94(8):558-558A. https://doi.org/10.2471/BLT.16.181743 .
doi: 10.2471/BLT.16.181743
pubmed: 27516629
pmcid: 4969997
Jakovljevic M, Lazarevic M, Milovanovic O, et al. The new and old Europe: east-west split in pharmaceutical spending. Front Pharmacol. 2016;7:18. https://doi.org/10.3389/fphar.2016.00018 .
doi: 10.3389/fphar.2016.00018
pubmed: 26973521
pmcid: 4771948
Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. https://doi.org/10.1016/S1473-3099(18)30605-4 .
doi: 10.1016/S1473-3099(18)30605-4
pubmed: 30409683
pmcid: 6300481
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. CAESAR Annual report, 2019. https://www.euro.who.int/__data/assets/pdf_file/0003/418863/53373-WHO-CAESAR-annual-report-2019.pdf . Accessed 21 Dec 2021.
Ruiz-Garbajosa P, Cantón R. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa Implications for empiric and definitive therapy. Rev Esp Quimioter. 2017;30(Suppl 1):8–12.
pubmed: 28882007
World Health Organization. Republic of Serbia: National antibiotic resistance control programme for the period 2019–2021. Switzerland: World Health Organization; 2019.
doi: 10.1596/31951
Medic D, Bozic Cvijan B, Bajcetic M. Impact of antibiotic consumption on antimicrobial resistance to invasive hospital pathogens. Antibiotics. 2023;12:259. https://doi.org/10.3390/antibiotics12020259 .
doi: 10.3390/antibiotics12020259
pubmed: 36830170
pmcid: 9952588
European centre for disease prevention and control (ECDC). TESSy, The European surveillance system – antimicrobial consumption (AMC) reporting protocol 2023 – European surveillance of antimicrobial consumption network (ESAC-Net) surveillance data for 2022. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/esac-net-reporting-protocol-2023 . Accessed 15 Dec 2021.
Working group for the development of a national guide to good clinical practice for the rational use of antibiotics, Ministry of health of Republic of Serbia. National guide to good clinical practice for the rational use of antibiotics. Belgrade; 2018. https://www.zdravlje.gov.rs/view_file.php?file_id=527&cache=sr . Accessed 15 Dec 2021.
Tomas A, Pavlović N, Stilinović N, et al. Increase and change in the pattern of antibiotic use in Serbia (2010–2019). Antibiotics. 2021;10:397. https://doi.org/10.3390/antibiotics10040397 .
doi: 10.3390/antibiotics10040397
pubmed: 33916896
pmcid: 8067575
Krantz EM, Zier J, Stohs E, et al. Antibiotic prescribing and respiratory viral testing for acute upper respiratory infections among adult patients at an ambulatory cancer center. Clin Infect Dis. 2020;70(7):1421–8. https://doi.org/10.1093/cid/ciz409 .
doi: 10.1093/cid/ciz409
pubmed: 31095276
Lukovic JA, Miletic V, Pekmezovic T, et al. Self-medication practices and risk factors for self-medication among medical students in Belgrade, Serbia. PLoS ONE. 2014;9(12):e114644. https://doi.org/10.1371/journal.pone.0114644 .
doi: 10.1371/journal.pone.0114644
pubmed: 25503967
pmcid: 4263675
Tripković K, Nešković A, Janković J, et al. Predictors of self-medication in Serbian adult population: cross-sectional study. Int J Clin Pharm. 2018;40(3):627–34. https://doi.org/10.1007/s11096-018-0624-x .
doi: 10.1007/s11096-018-0624-x
pubmed: 29603073
Kusturica MP, Tomic Z, Bukumiric Z, et al. Home pharmacies in Serbia: an insight into self-medication practice. Int J Clin Pharm. 2015;37(2):373–8. https://doi.org/10.1007/s11096-015-0071-x . (Epub 2015 Jan 24 PMID: 25616627).
doi: 10.1007/s11096-015-0071-x
pubmed: 25616627
Tomas A, Paut Kusturica M, Tomić Z, et al. Self-medication with antibiotics in Serbian households: a case for action? Int J Clin Pharm. 2017;39:507–13. https://doi.org/10.1007/s11096-017-0461-3 .
doi: 10.1007/s11096-017-0461-3
pubmed: 28391441
Earnshaw S, Mancarella G, Mendez A, et al. European antibiotic awareness day technical advisory committee. European antibiotic awareness day collaborative group european antibiotic awareness day: a five-year perspective of Europe-wide actions to promote prudent use of antibiotics. Euro Surveill. 2014;19(41):20928. https://doi.org/10.2807/1560-7917.es2014.19.41.20928 .
doi: 10.2807/1560-7917.es2014.19.41.20928
pubmed: 25345519
Reports on turnover and use of medicines of the Medicines and medical devices agency of Serbia. https://www.alims.gov.rs/ciril/o-agenciji/publikacije/ . Accessed 17 Aug 2022.
World Health Organization. WHO collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment 2023. Oslo, Norway, 2022. https://www.whocc.no/filearchive/publications/2023_guidelines_web.pdf . Accessed 16 Mar 2023.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. CAESAR manual, version 3, 2019. https://apps.who.int/iris/bitstream/handle/10665/346572/WHO-EURO-2019-3583-43342-60804-eng.pdf?sequence=1&isAllowed=y . Accessed 22 Dec 2021.
World Health Organization (WHO). WHO access, watch, reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021. Geneva: WHO; 2021 (WHO/MHP/HPS/EML/2021.04). Available from: https://www.who.int/publications/i/item/2021-aware-classification . Accessed 16 Mar 2023.
Reports on the resistance of invasive bacterial isolates to antimicrobial drugs of Institute of public health of Vojvodina. http://www.izjzv.org.rs/ . Accessed 26 Jul 2022.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. 2018. https://apps.who.int/iris/handle/10665/324806 . Accessed 3 Aug 2022.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. 2020. https://apps.who.int/iris/handle/10665/345873 . Accessed 3 Aug 2022.
WHO Regional office for Europe/European centre for disease prevention and control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. https://www.who.int/europe/publications/i/item/9789289056687 . Accessed 3 Aug 2022.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. 2017. https://apps.who.int/iris/bitstream/handle/10665/342131/9789289052993-eng.pdf?sequence=1&isAllowed=y . Accessed 3 Aug 2022.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. 2016. https://apps.who.int/iris/bitstream/handle/10665/344085/9789289052252-eng.pdf?sequence=2&isAllowed=y . Accessed 3 Aug 2022.
World Health Organization. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. 2014. https://apps.who.int/iris/bitstream/handle/10665/344413/9789289051088-eng.pdf?sequence=1&isAllowed=y . Accessed 3 Aug 2022.
Antimicrobial resistance dashboard. Copenhagen: WHO regional office for Europe; 2022 https://worldhealthorg.shinyapps.io/WHO-AMR-Dashboard-main/ . Accessed 15 Mar 2023.
Reports on turnover and use of medicines of the agency for medicinal products and medical devices of Croatia. https://www.halmed.hr/Promet-proizvodnja-i-inspekcija/Promet/Potrosnja-lijekova/Izvjesca-o-prometu-lijekova/ . Accessed 17 Aug 2022.
European centre for disease prevention and control. Latest surveillance data on antimicrobial consumption. Antimicrobial consumption dashboard (ESAC-Net). AMC | European Centre for Disease Prevention and Control. https://qap.ecdc.europa.eu/public/extensions/AMC2_Dashboard/AMC2_Dashboard.html#eu-consumption-tab . Accessed 8 Mar 2023.
European centre for disease prevention and control. Antimicrobial resistance in the EU/EEA (EARS-Net) - annual Epidemiological report 2019. Country summaries - antimicrobial resistance in the EU/EEA 2019. Stockholm: ECDC; 2020. https://www.ecdc.europa.eu/sites/default/files/documents/Country%20summaries-AER-EARS-Net%20202019.pdf . Accessed 15 Mar 2023.
European centre for disease prevention and control. Antimicrobial resistance in the EU/EEA (EARS-Net) - annual epidemiological report 2020. Country summaries - antimicrobial resistance in the EU/EEA 2020. Stockholm: ECDC; 2022. https://www.ecdc.europa.eu/sites/default/files/documents/AER_EARS-Net%202020%20country-summaries.pdf . Accessed 15 Mar 2023.
Reports on turnover and use of medicines of Institute for medicines and medical devices of Montenegro. https://www.cinmed.me/ . Accessed 17 Aug 2022.
Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3%3c335::aid-sim336%3e3.0.co;2-z.Erratum.In:StatMed2001Feb28;20(4):655 . (PMID: 10649300).
doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z.Erratum.In:StatMed2001Feb28;20(4):655
pubmed: 10649300
Dragomirescu I, Llorca J, Gómez IA, et al. A join point regression analysis of trends in mortality due to osteoporosis in Spain. Sci Rep. 2019;9(1):4264. https://doi.org/10.1038/s41598-019-40806-0 .
doi: 10.1038/s41598-019-40806-0
pubmed: 30862942
pmcid: 6414692
Despotović A, Barać A, Cucanić T, et al. Antibiotic (Mis) use in COVID-19 patients before and after admission to a tertiary hospital in Serbia. Antibiotics. 2022;11:847. https://doi.org/10.3390/antibiotics11070847 .
doi: 10.3390/antibiotics11070847
pubmed: 35884101
pmcid: 9311622
Zivanovic V, Bukarica LG, Scepanovic R, et al. Differences in antimicrobial consumption, prescribing and isolation rate of multidrug resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii on surgical and medical wards. PLoS ONE. 2017;12(5):e0175689. https://doi.org/10.1371/journal.pone.0175689 .
doi: 10.1371/journal.pone.0175689
pubmed: 28467437
pmcid: 5415063
Djordjevic ZM, Folic MM, Jankovic SM. Previous antibiotic exposure and antimicrobial resistance patterns of Acinetobacter spp and Pseudomonas aeruginosa isolated from patients with nosocomial infections. Balkan Med J. 2017;34:527–33. https://doi.org/10.4274/balkanmedj.2016.1844 .
doi: 10.4274/balkanmedj.2016.1844
pubmed: 29215335
pmcid: 5785657
Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. Am J Transp. 2016;16(7):2224–30. https://doi.org/10.1111/ajt.13893 .
doi: 10.1111/ajt.13893
Mancini A, Verdini D, La Vigna G, et al. Retrospective analysis of nosocomial infections in an Italian tertiary care hospital. New Microbiol. 2016;39(3):197–205.
pubmed: 27284985
Goel N, Wattal C, Oberoi JK, et al. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi. India J Antimicrob Chemother. 2011;66(7):1625–30. https://doi.org/10.1093/jac/dkr167 .
doi: 10.1093/jac/dkr167
pubmed: 21586594
European centre for disease prevention and control. Surveillance of antimicrobial resistance in Europe – annual report of the European antimicrobial resistance surveillance network (EARS-Net) 2017. Stockholm: ECDC; 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AMR%202017_Cover%2BInner-web_v3.pdf . Accessed 20 Dec 2021.
European centre for disease prevention and control. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European antimicrobial resistance surveillance network (EARS-Net). Stockholm: ECDC; 2017. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf . Accessed 20 Dec 2021.
Mladenovic-Antic S, Kocic B, Velickovic-Radovanovic R, et al. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study. J Clin Pharm Ther. 2016;41(5):532–7. https://doi.org/10.1111/jcpt.12432 .
doi: 10.1111/jcpt.12432
pubmed: 27511808
Peñalva G, Högberg LD, Weist K, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24(46):1900656. https://doi.org/10.2807/1560-7917.ES.2019.24.46.1900656 .
doi: 10.2807/1560-7917.ES.2019.24.46.1900656
pubmed: 31771708
pmcid: 6864974